Prelude Therapeutics to Participate in Barclays Global Healthcare Conference
Prelude Therapeutics Incorporated (Nasdaq: PRLD) will participate in the Barclays Global Healthcare Conference. The CEO and Chief Medical Officer will be part of a fireside chat on March 13, 2024. The event will be live webcasted and archived on the company's website.
02/29/2024 - 04:05 PM
WILMINGTON, Del., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Prelude) (Nasdaq: PRLD), a clinical-stage precision oncology company, announced today that the Company will participate in the Barclays Global Healthcare Conference in Miami, March 12-14, 2024.
On Wednesday, March 13, at 3:05 p.m. ET, Kris Vaddi, Ph.D., Chief Executive Officer of Prelude, and Jane Huang, M.D., President and Chief Medical Officer, will participate in a fireside chat, hosted by Barclays.
A live webcast of the fireside chat can be accessed here and on the Company’s website under Events and Presentations . The recording will be archived and available on the Company’s website for 90 days.
About Prelude Therapeutics
For more information, visit our website and follow us on LinkedIn .
Investor Contact: ltrickett@preludetx.com Media Contact: Helen@ShikCommunications.com
When will Prelude Therapeutics participate in the Barclays Global Healthcare Conference?
Prelude Therapeutics will participate in the Barclays Global Healthcare Conference on March 12-14, 2024.
Who will be part of the fireside chat at the conference?
Kris Vaddi, Ph.D., Chief Executive Officer, and Jane Huang, M.D., President and Chief Medical Officer, will participate in the fireside chat.
Where can the live webcast of the fireside chat be accessed?
The live webcast of the fireside chat can be accessed on the company's website under Events and Presentations.
How long will the recording of the fireside chat be available on the company's website?
The recording of the fireside chat will be archived and available on the company's website for 90 days.
PRLD Rankings
#5192 Ranked by Stock Gains
PRLD Stock Data
Industry
Pharmaceutical Preparation Manufacturing
Sector
Manufacturing
Tags
Health Technology, Biotechnology
About PRLD
prelude therapeutics incorporated, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule therapies optimized to target the key driver mechanisms in cancers. it is developing prt543 that is in phase 1 clinical trials in select solid tumors and myeloid malignancies in patients who are refractory to or intolerant of established therapies; and prt811, which is in phase 1 clinical trials in solid tumors, including glioblastoma multiforme and primary central nervous system lymphomas. the company is also developing prt1419, a potent and selective inhibitor of the anti-apoptotic protein; prt2527, a potent inhibitor of cdk9 that exhibits high kinome selectivity; prt-sca2 for multiple genomically selected cancers; and prt-k4 for solid tumors. prelude therapeutics incorporated was founded in 2016 and is based in wilmington, delaware.
